Adds Regeneron comment Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen ...
Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...
This was the stock's third consecutive day of losses.
The teen is the first student from Levittown's General Douglas MacArthur High School to be named a finalist in the ...
Wen is among the 40 finalists heading to Washington, D.C., Thursday to present their projects to panels of experts. The ...
Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...
Regeneron’s DB-OTO: Overcoming Clinical and Manufacturing Hurdles in Gene Therapy for Hearing Loss
Jonathon Whitton, AuD, PhD, VP, auditory global program head, Regeneron, discusses regulatory challenges for DB-OTO, Regeneron’s AAV-based gene therapy for hearing loss.
It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
At the CIO 100 Symposium and Awards, Lee Rennick, executive director of CIO Communities for CIO.com, sat with Bob McCowan, SVP and CIO at Regeneron Pharmaceuticals, and discussed their award-winning ...
This was the stock's second consecutive day of losses.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results